
## Michael A Gordon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5369097/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Research, 2015, 75, 4651-4664.	0.9	216
2	Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i> . Molecular Cancer Therapeutics, 2015, 14, 769-778.	4.1	184
3	Cooperative Dynamics of AR and ER Activity in Breast Cancer. Molecular Cancer Research, 2016, 14, 1054-1067.	3.4	114
4	The long nonâ€coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2â€mediated alternative splicing. Molecular Carcinogenesis, 2019, 58, 196-205.	2.7	91
5	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Hormones and Cancer, 2015, 6, 206-213.	4.9	88
6	Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. Molecular Cancer Research, 2019, 17, 30-41.	3.4	49
7	Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Molecular Cancer Therapeutics, 2017, 16, 1389-1400.	4.1	44
8	Anti-androgen therapy in triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2016, 8, 305-308.	3.2	21
9	Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs <i>de novo</i> lipogenesis. Development (Cambridge), 2016, 143, 4236-4248.	2.5	19
10	Dicer expression in estrogen receptor–positive versus triple-negative breast cancer: an antibody comparison. Human Pathology, 2016, 56, 40-51.	2.0	9